Balloon Angioplasty News and Research

RSS

Balloon Angioplasty is a procedure to enlarge the opening in a blood vessel that has become narrowed or blocked by plaque (a buildup of fat and cholesterol on the inner wall of the blood vessel). A small balloon is filled with air inside the blood vessel to push the plaque against the blood vessel wall and increase the opening.

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

First patient enrolled for IDEV Technologies' SUPERB clinical trial

IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).

25 Aug 2009

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fourth quarter and fiscal year ended June 30, 2009.

19 Aug 2009

New drug promises to reduce damage from a heart attack

Research into a new drug by Australian heart experts has found that it can dramatically reduce heart muscle damage after a heart attack.

28 Jul 2009

New drug may reduce heart attack damage

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

22 Jul 2009

Diabetes with coronary disease: A moving target amid evolving therapies

In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."

8 Jun 2009

FHL2 protein regulates blood vessel maintenance

In a study led by Akiko Hata, PhD, of Tufts University School of Medicine, researchers have shown that a protein expressed in the heart, FHL2, inhibits the genes necessary for the quiescence of vascular smooth muscle cells (vSMCs), which line blood vessels.

12 May 2009

Healthcare reform should start with paying evidence-based financial incentives to doctors

Healthcare Reform should start with "evidence-based reimbursement", structuring physician payment incentives around existing empirical evidence of clinical benefit, which would improve quality and reduce the cost of healthcare, says a commentary written by two cardiologists and published in Circulation: Cardiovascular Quality and Outcomes .

20 Apr 2009

Heart bypass surgery better than angioplasty for certain patients

After three years working with investigators from 10 different clinical trials around the world from Brazil to London to Pittsburgh, Stanford University School of Medicine researchers have pooled enough individual patient data to compare the effectiveness of coronary artery bypass surgery with the less-invasive angioplasty procedure on specific groups of patients for the first time.

20 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Saving limbs with drug-eluting stents

Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene) and amputation.

11 Mar 2009

Saving heart attack patients in the middle of the night

When Joyce Moss recently arrived at Loyola University Hospital with a life-threatening heart attack, it took just 42 minutes to perform an emergency balloon angioplasty.

5 Mar 2009

Statins can stimulate cardiac muscle cell regeneration, improve heart function

Statins, used widely to treat elevated cholesterol, have been shown to prevent progression of coronary narrowing and to have other beneficial effects on the heart, such as reducing inflammation, that are independent of cholesterol.

23 Feb 2009

Senior patients benefit from selective use of early revascularization

The elderly represent a growing proportion of patients presenting with acute myocardial infarction (MI) complicated by cardiogenic shock (CS).

16 Feb 2009

Nontoxic nanoparticle delivers and tracks drugs

A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.

18 Nov 2008

Timing is everything for some heart attack patients

There is strong evidence that getting to the hospital quickly during a heart attack is critical, since early treatment saves both lives and heart muscle. And if the responsible coronary artery is completely blocked, it should be opened as soon as possible.

11 Nov 2008

Drug-releasing coronary artery stent use linked with decrease in procedures to unblock coronary arteries

The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association

24 Jun 2008

Bivalirudin improves net clinical outcomes and increases survival in heart attack patients

A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events, a lower rate of major bleeding, and a lower mortality rate than those who were treated with a regimen of heparin and glycoprotein IIb/IIIa inhibitors (GPI).

26 May 2008

Novel drug shows promise in limiting heart attack damage

A novel drug designed to lessen muscle damage from a heart attack has passed initial safety tests at the Duke Clinical Research Institute.

8 Feb 2008

Patients at risk of adverse events within 3 months after stopping certain ACS therapy

Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the February 6 issue of JAMA: The Journal of the American Medical Association.

7 Feb 2008